X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs SUN PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA SUN PHARMA CIPLA/
SUN PHARMA
 
P/E (TTM) x 33.8 35.1 96.5% View Chart
P/BV x 2.9 2.7 108.4% View Chart
Dividend Yield % 0.6 0.5 123.8%  

Financials

 CIPLA   SUN PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-18
SUN PHARMA
Mar-18
CIPLA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs663701 94.6%   
Low Rs479433 110.6%   
Sales per share (Unadj.) Rs189.0110.4 171.2%  
Earnings per share (Unadj.) Rs17.611.0 160.3%  
Cash flow per share (Unadj.) Rs34.017.2 197.5%  
Dividends per share (Unadj.) Rs3.002.00 150.0%  
Dividend yield (eoy) %0.50.4 148.9%  
Book value per share (Unadj.) Rs176.7158.8 111.3%  
Shares outstanding (eoy) m805.122,399.26 33.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.05.1 58.8%   
Avg P/E ratio x32.551.6 62.8%  
P/CF ratio (eoy) x16.832.9 51.0%  
Price / Book Value ratio x3.23.6 90.5%  
Dividend payout %17.118.2 93.6%   
Avg Mkt Cap Rs m459,7241,360,021 33.8%   
No. of employees `00023.617.8 132.7%   
Total wages/salary Rs m26,90153,671 50.1%   
Avg. sales/employee Rs Th6,446.114,890.9 43.3%   
Avg. wages/employee Rs Th1,139.43,017.1 37.8%   
Avg. net profit/employee Rs Th600.01,480.6 40.5%   
INCOME DATA
Net Sales Rs m152,193264,895 57.5%  
Other income Rs m3,5778,388 42.6%   
Total revenues Rs m155,769273,282 57.0%   
Gross profit Rs m28,26456,081 50.4%  
Depreciation Rs m13,22814,998 88.2%   
Interest Rs m1,1425,176 22.1%   
Profit before tax Rs m17,47044,295 39.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m-280-   
Extraordinary Inc (Exp) Rs m-775-9,505 8.2%   
Tax Rs m2,5018,452 29.6%   
Profit after tax Rs m14,16626,338 53.8%  
Gross profit margin %18.621.2 87.7%  
Effective tax rate %14.319.1 75.0%   
Net profit margin %9.39.9 93.6%  
BALANCE SHEET DATA
Current assets Rs m108,141316,359 34.2%   
Current liabilities Rs m38,322198,643 19.3%   
Net working cap to sales %45.944.4 103.2%  
Current ratio x2.81.6 177.2%  
Inventory Days Days9795 102.3%  
Debtors Days Days74108 69.1%  
Net fixed assets Rs m109,411213,178 51.3%   
Share capital Rs m1,6102,399 67.1%   
"Free" reserves Rs m140,682378,606 37.2%   
Net worth Rs m142,292381,006 37.3%   
Long term debt Rs m36,62117,721 206.7%   
Total assets Rs m228,606643,028 35.6%  
Interest coverage x16.39.6 170.5%   
Debt to equity ratio x0.30 553.3%  
Sales to assets ratio x0.70.4 161.6%   
Return on assets %6.74.9 136.6%  
Return on equity %10.06.9 144.0%  
Return on capital %10.010.0 99.3%  
Exports to sales %32.80-   
Imports to sales %00-   
Exports (fob) Rs m49,883NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,69140,816 126.6%   
Fx outflow Rs m21,03330,143 69.8%   
Net fx Rs m30,65810,673 287.2%   
CASH FLOW
From Operations Rs m14,62839,072 37.4%  
From Investments Rs m-8,540-33,708 25.3%  
From Financial Activity Rs m-3,855-15,393 25.0%  
Net Cashflow Rs m2,431-7,359 -33.0%  

Share Holding

Indian Promoters % 16.0 63.7 25.1%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 5.1 237.8%  
FIIs % 23.7 23.0 103.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 8.3 315.7%  
Shareholders   161,166 133,026 121.2%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   UNICHEM LAB  AUROBINDO PHARMA  PFIZER  GLENMARK PHARMA  VENUS REMEDIES  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open on a Positive Note; Realty & Auto Stocks Lead(09:30 am)

Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.2% while the Hang Seng is up 1.6%.

Related Views on News

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Dec 12, 2018 10:11 AM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS